Clinical Trials Logo
  1. Home
  2. Carcinomas
  3. NCT00935675

Double-blind, Placebo-controlled, Randomized Study of the Effectiveness of Escitalopram on Emotional Distress of Head and Neck Cancer Patients During Cancer Treatment

Carcinomas Clinical Trial

Clinical Trial Summary

Evaluation of the effectiveness of escitalopram on depressive symptoms after 3 months in patients with head and neck squamous cell carcinomas (oral cavity, larynx, oropharynx and hypopharynx) and with an HADS total score > 11

Clinical Trial Description

n/a

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT00935675
Study type Interventional
Source Gustave Roussy, Cancer Campus, Grand Paris
Contact
Status Recruiting
Phase Phase 3
View Details
See also
  Status Clinical Trial Phase
Recruiting NCT05347212 - Phase II Trial of Immunotherapy in Patients With Carcinomas Arising From the Renal Medulla Phase 2
Withdrawn NCT01148082 - School Response to Families Who Have Children With Cancer N/A
Completed NCT01135849 - B-Receptor Signaling in Cardiomyopathy N/A
Recruiting NCT05642195 - Evaluation of a Cancer Lysate Vaccine and Montanide (Registered Trademark) ISA-51 VG With or Without the IL-15 Super-Agonist N-803 as Adjuvant Therapy for PD-L1 Negative Non-Small Cell Lung Cancer Phase 1/Phase 2
Completed NCT01135823 - Symptom Assessment With Patient Surveys N/A
Active, not recruiting NCT05063916 - Phase II Study of AK104 (Cadonilimab) for Recurrent Small Cell Neuroendocrine Carcinomas of the Cervix Phase 2
Completed NCT01026415 - Clinical Pharmacology Study of Brentuximab Vedotin (SGN-35) Phase 1